Aegerion/Novelion Therapeutics/Amryt Pharma: Represented global biopharmaceutical company Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.
Constellation Pharmaceuticals/MorphoSys: Represented Constellation Pharmaceuticals in connection with MorphoSys’s acquisition of Constellation Pharmaceuticals.
Ekkio/Q-Biologicals: Represented Ekkio and its portfolio company, Amatsigroup, in the acquisition of Q-Biologicals, a leading provider of process development and biomanufacturing services.
Galil Medical/BTG: Represented certain shareholders of cryotherapy company Galil Medical in its sale to BTG plc.
Hansen Medical/Auris Surgical Robots: Advised funds owned by Oracle Management and other majority stockholders of Hansen Medical, Inc. in the acquisition of Hansen Medical by Auris Surgical Robotics, Inc., as well as the related re-investment by such stockholders of their proceeds into Auris.
Horizon Therapeutics/Amgen: Advised Morgan Stanley as financial advisor to Horizon Therapeutics in its $27.8 billion acquisition by Amgen.
NextPharma/Lonza: Represented NextPharma on its agreement to acquire the Ploermel and Edinburgh production sites of biotechnology company Lonza.
Tikehau/Cisbio Bioassays/Abenex: Represented Tikehau on the financing aspects of the acquisition of Cisbio Bioassays by Abenex.
Qualium Investissement/Lauxera Capital Partners/VERDOT Ips²
: Represented Qualium Investissement and Lauxera Capital Partners in their acquisition of a majority stake in VERDOT Ips².